Allopurinol Versus Febuxostat Use and the Risk of Cardiovascular Disease in People With Chronic Kidney Disease: A New‐User Active Comparator Cohort Study
In conclusion, no statistically significant difference in the risk of cardiovascular events was observed in people with chronic kidney disease who were newly prescribed febuxostat compared with those newly treated with allopurinol.
Authors
- Satoko Yamaguchi (ORCID: https://orcid.org/0000-0003-2822-2281)
- Akira Okada (ORCID: https://orcid.org/0000-0001-6480-3388)
- Toshimasa Yamauchi (ORCID: https://orcid.org/0000-0003-4827-6404)
- Masaomi Nangaku (ORCID: https://orcid.org/0000-0001-7401-2934)
- Takashi Kadowaki (ORCID: https://orcid.org/0000-0002-5428-3582)
- Daisuke Inoue (ORCID: https://orcid.org/0009-0005-5842-2147)
Institutions
- Toranomon Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Nephrology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1111/nep.70149
- Citations
- 1
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- Ministry of Education, Culture, Sports, Science and Technology